Tempus AI, Inc. (TEM)
Tempus AI Stock Before Q4 Earnings Release: To Buy or Not to Buy?
TEM heads into Q4 earnings with expected 82.8% revenue growth, rising oncology momentum and a premium valuation clouding near-term upside.
Tempus AI & Median Partner to Add AI Lung Cancer Screening to Pixel
TEM teams with Median to add FDA-cleared eyonis LCS to Pixel, boosting AI lung cancer screening and expanding its imaging portfolio.
Should You Buy, Hold or Sell Tempus AI Stock Pre-Q4 Earnings Release?
In preliminary, unaudited financial results, TEM posts 83% revenue growth and record data sales in 2025, but valuation and ongoing GAAP losses cloud the outlook before Q4 earnings.
TEM vs. DOCS: Which Medical-Tech Stock Looks Promising Amid AI Boom?
AI momentum is reshaping med-tech, with Tempus AI scaling diagnostics and Doximity leveraging platform-wide AI, strong margins, and cash flow to gain an edge.
How TEM Is Capitalizing on AI-Driven Pathology Market Growth
Tempus AI boosts AI pathology reach by acquiring Paige and launching Paige Predict to deliver biomarker insights across 16 cancer types.
Tempus AI: Staying Bullish On Leading Healthcare AI Play
Tempus AI (TEM) remains a resilient healthcare AI leader, with proprietary data driving traction and a clear buy opportunity amid recent volatility. TEM reported preliminary 2025 revenue of ~$1.27B (+30% organic growth) and >$1.1B total contract value, supporting a robust multi-year growth runway. 2026 guidance calls for 25% revenue growth to $1.59B and adjusted EBITDA expansion to ~$65M, with management reinvesting two-thirds of incremental profit.
Tempus AI's Key 2025 Milestones Continue to Gain Industry Attention
TEM hits $1.1B TCV, signs 70+ pharma data deals and posts its first positive adjusted EBITDA in Q3 2025 as adoption accelerates.
TEM's Collab for Oncology Patient Population Is Gaining Attention
Tempus AI's partnerships with NYU Langone and Northwestern Medicine aim to expand genomic testing and data-driven cancer care.
Tempus AI, Inc. (TEM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Tempus AI, Inc. (TEM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Tempus AI Stock Rallies 105% in a Year: Should Investors Still Hold?
TEM has surged 105% in a year on AI-driven growth, FDA clearances and improving margins, but GAAP losses still cloud the outlook.
Tempus AI Stock Surges 82.4% in a Year: What's Driving It?
TEM shares are up 82.4% in a year as Genomics revenues surge, Data & Services scale, FDA clearances and EBITDA turns positive.
TEM's Stable Solvency and Financial Strength Are Gaining Attention
Tempus AI posts a strong Q3 2025 balance sheet with $760M cash, no current debt, and positive adjusted EBITDA, boosting flexibility and solvency.
